Brii Biosciences is expanding the scope of its license for an investigational hepatitis B virus (HBV) immunotherapy drug and taking on an HBV vaccine in its more than four-year-old partnership with VBI Vaccines Inc., months after Phase II data for the drug demonstrated promising tolerability and antibody responses.
The two companies said 5 July that Brii Bio would expand its exclusive license for the HBV drug, VBI-2601/BRII-179, from an exclusive license to include global rights and acquire an exclusive license for VBI’s three-antigen HBV vaccine, PreHevbri, in the Asia-Pacific region
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?